26.60
1.18%
0.31
After Hours:
26.76
0.16
+0.60%
Royalty Pharma Plc stock is traded at $26.60, with a volume of 1.81M.
It is up +1.18% in the last 24 hours and down -1.30% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$26.29
Open:
$26.345
24h Volume:
1.81M
Relative Volume:
0.80
Market Cap:
$11.79B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
236.44
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
+1.45%
1M Performance:
-1.30%
6M Performance:
-0.08%
1Y Performance:
-1.99%
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
26.60 | 11.79B | 2.24B | 673.24M | 2.67B | 0.1125 |
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-03-24 | Downgrade | UBS | Buy → Neutral |
Jun-14-22 | Resumed | UBS | Buy |
May-13-22 | Initiated | Scotiabank | Sector Outperform |
Apr-27-22 | Initiated | Goldman | Buy |
Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-06-22 | Resumed | Morgan Stanley | Overweight |
Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
Jul-30-21 | Initiated | Tigress Financial | Buy |
Nov-09-20 | Upgrade | UBS | Neutral → Buy |
Jul-14-20 | Initiated | Evercore ISI | In-line |
Jul-13-20 | Initiated | BofA Securities | Buy |
Jul-13-20 | Initiated | Citigroup | Neutral |
Jul-13-20 | Initiated | Cowen | Outperform |
Jul-13-20 | Initiated | Goldman | Neutral |
Jul-13-20 | Initiated | JP Morgan | Neutral |
Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
Jul-13-20 | Initiated | SunTrust | Buy |
Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times
Royalty Pharma to Present at Two Major Healthcare Investor Conferences in December | RPRX Stock News - StockTitan
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - Insider Monkey
Dai ichi Life Insurance Company Ltd Has $4.79 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Qsemble Capital Management LP Buys New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
10 Cheapest Stocks to Buy On Robinhood - Insider Monkey
(RPRX) Trading Advice - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Thrivent Financial for Lutherans Purchases 168,905 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Overbrook Management Corp Sells 59,504 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Victory Capital Management Inc. - MarketBeat
RPRXRoyalty Pharma plc Latest Stock News & Market Updates - StockTitan
Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Simplify Asset Management Inc. - MarketBeat
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool
Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat
Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q3 2024 Earnings Preview - MSN
Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat
Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha
Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com
Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance
Royalty Pharma Reports Strong Q3 2024 Results - TipRanks
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria
Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
Avara Management Ltd | 10% Owner |
Dec 15 '23 |
Sale |
28.01 |
10,229 |
286,499 |
2,794,915 |
Avara Management Ltd | 10% Owner |
Dec 14 '23 |
Sale |
28.91 |
364,441 |
10,534,276 |
2,805,144 |
Avara Management Ltd | 10% Owner |
Dec 13 '23 |
Sale |
28.95 |
307,935 |
8,916,012 |
3,169,585 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):